Currently, many treatments for demyelinating diseases include injectable drugs that are not specific but suppress the general immune response leading to many negative side effects; thus, the development of therapeutic agents able to specifically control and modulate Th17 cells activity, pivotal players in the CNS inflammation, is an urgent need.Our group has gained experience in the design, synthesis, structural and biological characterization of new peptide-based molecules selective for different type of integrins. To this regard, our aim is to develop αvβ3 integrin antagonists able to selectively modulate the receptor activity in EAE and with high enzymatic stability for obtaining orally administrated drugs. Thanks to the collaboration with Prof. Mandy J. McGeachy from University of Pittsburghthe ability of the peptides in the modulation of Th17 function in EAE model is investigated.
- Du, F. et al. Inflammatory Th17 Cells Express Integrin αvβ3 for Pathogenic Function. Cell Reports 2016, 16, 1339. doi:10.1016/j.celrep.2016.06.065
- Comegna, D. et al. Chemical Modification for Proteolytic Stabilization of the Selective alpha(v)beta(3) Integrin RGDechi Peptide: in Vitro and in Vivo Activities on Malignant Melanoma Cells. J Med Chemv 2017, 60, 9874. doi: 10.1021/acs.jmedchem.7b01590
- Del Gatto, A. et al. Novel and selective alpha(v)beta(3) receptor peptide antagonist: Design, synthesis, and biological behavior. J Med Chem 2006, 49, 3416. doi: 10.1021/jm060233m